Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.60 |
| ▸ | AGXT | P21549 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487714 | 1.00 | CYP3A4 (0.60) | CYP3A4IDO1AGXTMAOBTACR1 | |
| SCHEMBL27045093 | 0.91 | CYP3A4 (0.55) | CYP3A4IDO1AGXTMAOBTACR1 | |
| SCHEMBL10866481 | 0.87 | CYP3A4 (0.69) | CYP3A4IDO1AGXTMAOBTACR1 | |
| SCHEMBL649159 | 0.85 | TSHR (0.46) | CYP3A4IDO1AGXT | |
| SCHEMBL8880826 | 0.82 | CYP3A4 (0.53) | CYP3A4IDO1AGXTMAOBTACR1 | |
| SCHEMBL9628682 | 0.81 | TSHR (0.48) | IDO1AGXTMAOBKDM4E | |
| SCHEMBL10364822 | 0.80 | TAAR1 (0.59) | MAOBTAAR1ALOX5 | |
| SCHEMBL423396 | 0.80 | CYP3A4 (0.60) | CYP3A4IDO1AGXTMAOBTACR1 | |
| SCHEMBL22519891 | 0.79 | CYP3A4 (0.55) | CYP3A4IDO1AGXTMAOBTACR1 | |
| SCHEMBL791970 | 0.79 | CYP3A4 (0.64) | CYP3A4IDO1AGXTMAOBPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632892-B1 | METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2024-07-31 | — | — | EP | disclosed |
| CN-110799490-B | 3-arylpropionamide compound and method for producing 3-arylpropionate compound | 住友化学株式会社 | 2023-05-02 | — | — | CN | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11028056-B2 | Method for producing 3-arylpropionamide compound and 3-arylpropionic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-06-08 | — | — | US | disclosed |
| US-20200165209-A1 | METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND AND 3-ARYLPROPIONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-28 | — | — | US | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3632892-A1 | METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND AND 3-ARYLPROPIONIC ACID ESTER COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2020-04-08 | — | — | EP | disclosed |
| CN-110799490-A | Process for producing 3-arylpropionamide compound and process for producing 3-arylpropionate compound | 住友化学株式会社 | 2020-02-14 | — | — | CN | disclosed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | disclosed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | disclosed |
| US-20120295856-A1 | FREDERICAMYCIN DERIVATIVES | ZENTOPHARM GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CYP3A4 4072/4885IDO1 1285/4885AGXT 328/4885 |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | CYP3A4 3440/4885IDO1 442/4885AGXT 4712/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CYP3A4 4072/4885IDO1 1285/4885AGXT 328/4885 |
| US-20200165209-A1 | METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND AND 3-ARYLPROPIONIC ACID ESTER COMPOUND | AADAC, DDT, NAT1 | CYP3A4 210/4885IDO1 1084/4885AGXT 21/4885 |
| US-20120295856-A1 | FREDERICAMYCIN DERIVATIVES | NISCH, MYC, MANBA | CYP3A4 2289/4885IDO1 3084/4885AGXT 998/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | CYP3A4 4168/4885IDO1 1601/4885AGXT 893/4885 |
| US-11028056-B2 | Method for producing 3-arylpropionamide compound and 3-arylpropionic acid ester compound | AADAC, DDT, NAT1 | CYP3A4 210/4885IDO1 1084/4885AGXT 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.